FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 817 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 Non-pharmacological interventions – are they important to patients with cancer? October 27, 2026 Olaparib approved for 800 prostate and breast cancer patients in England April 11, 2023 ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland November 29, 2022 Load more HOT NEWS Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and... Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable... “Oncometabolite” Neutralizes Immune Cells Near Tumors
